Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Rises By 103.4%

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 24,000 shares, an increase of 103.4% from the June 30th total of 11,800 shares. Approximately 1.3% of the shares of the stock are sold short. Based on an average daily volume of 23,400 shares, the days-to-cover ratio is currently 1.0 days.

Tenax Therapeutics Price Performance

Shares of NASDAQ:TENX traded up $0.07 during midday trading on Friday, hitting $3.39. The company had a trading volume of 1,716 shares, compared to its average volume of 15,167. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $61.20. The business’s 50-day simple moving average is $3.32 and its 200-day simple moving average is $4.84.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities research analysts expect that Tenax Therapeutics will post -7.96 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Tenax Therapeutics in a report on Wednesday. They issued a “sell” rating for the company.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.